Johnson & Johnson's earnings call highlights strong operational growth in the fourth quarter, driven by the consumer segment and improved performance in the medical devices division.  While patent expirations continue to impact the pharmaceutical segment, management emphasizes investments in R&D, acquisitions, and global expansion as key drivers for future growth.  The company expects a continuation of the positive trends in 2010 and beyond.
[1]
